{"id":29683,"date":"2012-08-01T03:56:57","date_gmt":"2012-08-01T03:56:57","guid":{"rendered":"http:\/\/countingpips.com\/fx\/?p=29683"},"modified":"2012-08-01T03:56:58","modified_gmt":"2012-08-01T03:56:58","slug":"eli-lily-gets-downgrade-on-predicted-failure-of-alzheimers-drug","status":"publish","type":"post","link":"https:\/\/www.investmacro.com\/fx\/2012\/08\/01\/eli-lily-gets-downgrade-on-predicted-failure-of-alzheimers-drug\/","title":{"rendered":"Eli Lily Gets Downgrade On Predicted Failure of Alzheimer&#8217;s Drug"},"content":{"rendered":"<p><div id=\"grabDiv1767162\"><object id=\"GrabPlayer1767162\" width=\"542\" height=\"304\" type=\"application\/x-shockwave-flash\" align=\"middle\" data=\"http:\/\/player.grabnetworks.com\/swf\/GrabOSMFPlayer.swf?id=1767162&#038;content=v22e233bad44e762d18578f7767827816efbb1feb&#038;tgt=grabnetworks\"><param name=\"quality\" value=\"high\"\/><param name=\"allowScriptAccess\" value=\"always\"\/><param name=\"allowFullScreen\" value=\"true\"\/><param name=\"menu\" value=\"false\"\/><param name=\"wmode\" value=\"transparent\"\/><param name=\"movie\" value=\"http:\/\/player.grabnetworks.com\/swf\/GrabOSMFPlayer.swf?id=1767162&#038;content=v22e233bad44e762d18578f7767827816efbb1feb&#038;tgt=grabnetworks\"\/><\/object><\/p>\n<div id=\"overlay-adzone\" style=\"overflow:hidden; position:relative\"><\/div>\n<\/div>\n<p>Drugmaker Eli Lily (NYSE:LLY) receiving a downgrade from Jefferies this morning. The analyst firm&#8217;s said it downgraded the company because it expects Eli Lily&#8217;s Alzheimer&#8217;s treatment to tail in late-stage testing. Jefferies added that the drug only has a 25% chance of being effective in a niche population.Eli Lily&#8217;s rating is now underperform at Jefferies, down from a hold. The firm also dropped its price target to $35 from $37.Results from late-stage testing of the drug solanezumab is expected to be released some time this quarter. The big reason why analysts are worried is a similar drug tested by Pfizer and Johnson &#038; Johnson yielded very poor results. Currently, Eli Lily stock is down almost 1% to $43.98.<\/p>\n<p><img src='http:\/\/images.grab-media.com\/financial_news_network\/2012\/07\/31\/1_f3wi1gpw_thumb.jpg' \/><\/p>\n<p><!--post_img[http:\/\/images.grab-media.com\/financial_news_network\/2012\/07\/31\/1_f3wi1gpw_preview.jpg]--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Drugmaker Eli Lily (NYSE:LLY) receiving a downgrade from Jefferies this morning. The analyst firm&#8217;s said it downgraded the company because it expects Eli Lily&#8217;s Alzheimer&#8217;s treatment to tail in late-stage testing. Jefferies added that the drug only has a 25% chance of being effective in a niche population.Eli Lily&#8217;s rating is now underperform at Jefferies, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.investmacro.com\/fx\/2012\/08\/01\/eli-lily-gets-downgrade-on-predicted-failure-of-alzheimers-drug\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Eli Lily Gets Downgrade On Predicted Failure of Alzheimer&#8217;s Drug&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-29683","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/posts\/29683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/comments?post=29683"}],"version-history":[{"count":0,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/posts\/29683\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/media?parent=29683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/categories?post=29683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/tags?post=29683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}